- Home
- OTLK vs HOVR Comparison
OTLK vs HOVR Comparison
Compare OTLK & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | HOVR |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | Canada |
| Employees | 17 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 103.1M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | HOVR |
|---|---|---|
| Price | $0.56 | $1.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.50 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 8.1M | 644.3K |
| Earning Date | 02-13-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,413,535.00 | N/A |
| Revenue This Year | $2,048.59 | N/A |
| Revenue Next Year | $142.11 | $55.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.35 |
| 52 Week High | $3.39 | $4.18 |
Technical Indicators
Market Signals| Indicator | OTLK | HOVR |
|---|---|---|
| Relative Strength Index (RSI) | 22.80 | 59.12 |
| Support Level | $1.78 | $1.42 |
| Resistance Level | $2.03 | $1.67 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 2.64 | 97.17 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About HOVR New Horizon Aircraft Ltd.
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.